Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on May 27, 2021 1:36pm
93 Views
Post# 33276502

RE:RE:RE:RE:RE:RE:RE:RE:More volume/higher valuation? This is how to get there.

RE:RE:RE:RE:RE:RE:RE:RE:More volume/higher valuation? This is how to get there.I am not sure if it was intentional or not, but basically, I took it as the FDA meeting had already occurred and they were now working on the harmonization withthe EMA. I think he made that clear enough for us to safely assume that explanation for his comments. 

qwerty22 wrote:

Pwib I don't want to think I can read Paul's mind (I wish I could) but I thought it was an odd moment in the chat with Ed Nash when he seemed to say they'd had the chat with the fda and then backed off and said he didn't want to say if they had or had not had the chat (is that too many hads???). It was almost as if he didn't want to set any expectations on near term NASH announcements. It seemed to me he wanted people to focus on Fall NASH patient dosing and not think too much about how we'd get there. Great guidance on patient dosing, poor guidance on the intervening months.

We all know first the hiv Nash announcement fell flat and the the general Nash announcement was a bust even though moments like bringing in Loomba were inspired. Maybe by keeping his options open on timing he's looking to maximize the impact from all the future milestones. I'm starting to fantasize about a cascade of events, starting with onco summer safety data. As I've said I like the idea of thinking of cancer as being seen as the lead investable program, followed by NASH as the second string to the bow (a big glittering, risky prize). I know NASH would be closer to market but somehow cancer, if it hits it's 2020/2021 milestone positively, seems like a more easily understood investable package to me.

Anybody remember that moment, think it was odd?

 

SPCEO1 wrote: I think they know they really ahve a bad IR situation on their hands and are doing a deep dive to sort it out. That will take time and I suspect most of that time has already passed. As I noted in a recent post, they are likely just waiting for an event, like the NASH protocol announcement, to unveil their new, LSA inspired, approach to the capital markets. I imagine how long we have to wait on that depends a lot on the speed of which their conversations are going with the EMA. If so, there is reason to believe it may take longer than we would like as regulators are not known for their speed of action and Europe has a much worse covid situation still than we have here in North America.
 

 

PWIB123 wrote: I feel the same way.  It's the radio silence and lack of energy around the stock that is the hardest to wait out, especially when you see the selling, day after day after day.  I liken our insatiable desire for new news, anything, just a taste of what is to be, to a drug addict.  Everyone needs/wants just a little something to keep them content and going a little longer before completely giving in and up.  THTX has to also recognize this is reality.  

In my mind, there are enough clues to sit tight and wait for the company to do what they said they are going to do.  Hopefully, they'll begin to make time to start filling in marketing gaps while they operationalize the business, but it still feels like they are in a major paradigm shift as it relates to the company's future.  I don't know if we are giving them enough credit for what's happening behind the scenes, but it sure would be better if they could manage that and the concerns addressed here simultaneously.

I haven't been around as long as some of you, but I'm still upside down on my investment, and I intend to see this prospect through to the end.  I just can't see how major announcements coming soon don't start to get picked up and recognized regardless of what could be happening now.  I'm betting on something really special happening here.

 




<< Previous
Bullboard Posts
Next >>